Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-PD1 therapy-Reference-Cited by-同舟云学术

Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-PD1 therapy

Published:2024-03 Issue:3 Volume:43 Page:113877
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Li Zhong-Chen,Wang Jie,Liu He-Bin,Zheng Yi-Min,Huang Jian-Hang,Cai Jia-Bin,Zhang Lei,Liu Xin,Du Ling,Yang Xue-Ting,Chai Xiao-Qiang,Jiang Ying-Hua,Ren Zheng-Gang,Zhou Jian,Fan Jia,Yu De-Cai,Sun Hui-Chuan,Huang Cheng,Liu Feng^ORCID

Funder

National Natural Science Foundation of China

Fudan University

Shanghai Municipal Education Commission

China Academy of Space Technology

Publisher

Elsevier BV

Reference102 articles.

1. Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction;Kanwal;Gastroenterology,2019

2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA A Cancer J. Clin.,2018

3. Molecular therapies for HCC: Looking outside the box;Faivre;J. Hepatol.,2020

4. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial;Robert;Lancet,2014

5. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice;Chiu;Gastroenterology,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis;Cytokine & Growth Factor Reviews;2024-10

2. Recent developments in immunotherapy for gastrointestinal tract cancers;Journal of Hematology & Oncology;2024-08-09